Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin vs placebo in type 2 diabetes with chronic kidney disease
CTR20181822Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sotagliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Sanofi. Started Dec 2018; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20181822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181822.